Cited 0 times in Scipus Cited Count

Inosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study)

DC Field Value Language
dc.contributor.authorLee, JJ-
dc.contributor.authorYoon, JH-
dc.contributor.authorKim, SJ-
dc.contributor.authorYoo, HS-
dc.contributor.authorChung, SJ-
dc.contributor.authorLee, YH-
dc.contributor.authorKang, SY-
dc.contributor.authorShin, HW-
dc.contributor.authorSong, SK-
dc.contributor.authorHong, JY-
dc.contributor.authorSunwoo, MK-
dc.contributor.authorLee, JE-
dc.contributor.authorBaik, JS-
dc.contributor.authorSohn, YH-
dc.contributor.authorLee, PH-
dc.date.accessioned2022-10-24T05:53:34Z-
dc.date.available2022-10-24T05:53:34Z-
dc.date.issued2021-
dc.identifier.issn0009-9236-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/22331-
dc.description.abstractThe aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA). The IMPROVE-MSA trial was a randomized, double-blind, placebo-controlled trial in patients with MSA with no history of hyperuricemia-related disorders. The participants were assigned to placebo (n = 25) or IMP (n = 30) in a 1 to 1 ratio, and then followed up for 24 weeks. The primary end points included safety, tolerability, and alteration of the serum UA level during the follow-up period. The secondary end points were changes in scores of the unified MSA rating scale (UMSARS) and the Mini-Mental Status Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The total number of adverse events (AEs) and serious AEs was comparable between the active and placebo groups. Serum UA level (mg/dL) was significantly increased from baseline (active vs. placebo, 4.57 vs. 4.58; P = 0.98) to study end point (6.96 vs. 4.43; P < 0.001) in the active group compared with the placebo group (time × group interaction; P < 0.001). The change in UMSARS scores did not differ between the active and placebo groups. However, the active group showed better alterations in MoCA scores with nominal significance (P < 0.001) and tendency for better alterations in MMSE scores (P = 0.09) than the placebo group. Our data demonstrated that IMP treatment was generally safe and well-tolerated in patients with MSA. A further trial with a long-term follow-up is required to examine whether UA elevation will slow clinical progression in early MSA.-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInosine Monophosphate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultiple System Atrophy-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUric Acid-
dc.titleInosine 5'-Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE-MSA study)-
dc.typeArticle-
dc.identifier.pmid33064299-
dc.contributor.affiliatedAuthorYoon, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.1002/cpt.2082-
dc.citation.titleClinical pharmacology and therapeutics-
dc.citation.volume109-
dc.citation.number5-
dc.citation.date2021-
dc.citation.startPage1274-
dc.citation.endPage1281-
dc.identifier.bibliographicCitationClinical pharmacology and therapeutics, 109(5). : 1274-1281, 2021-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1532-6535-
dc.relation.journalidJ000099236-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse